Who owns GENB? 13F holders and whale ownership
GENB is tracked across public portfolios in Whale Analyzer. This page answers who owns GENB, which top funds are buying GENB, aggregate disclosed value, and recent position changes based on public data. Baker Bros. Advisors is the largest reported holder at $18M; the top five funds control 100.0% of reported ownership; institutions were net buying last quarter (2 increased, 0 reduced); the stock trades above the aggregate whale cost basis of $11.14. Top tracked holders include Baker Bros. Advisors and Jensen Huang.
Continue to the live GENB dashboardTop holders
| Investor | Reported value | Shares | Change |
|---|---|---|---|
| Baker Bros. Advisors 13F portfolio Baker Bros. Advisors holdings | $17.8M | 1.4M | New |
| Jensen Huang insider transaction profile NVIDIA Corp holdings | $10.4M | 833.3K | New |
Ownership concentration
Reported ownership of GENB is highly concentrated across tracked institutions.
- Single largest holder: 63.1% of reported ownership
- Top 5 holders: 100.0%
- Top 10 holders: 100.0%
Whale activity this quarter
Across 2 tracked institutions, 2 increased. Net positioning is net buying.
- Baker Bros. Advisors — Baker Bros. Advisors ($17.8M) · avg cost $11.22
- Jensen Huang — NVIDIA Corp ($10.4M) · avg cost $11.00
Whale cost basis vs current price
The aggregate tracked cost basis is $11.14 versus a current price of $16.47, so GENB trades above its cost basis (+47.9%). Average unrealized P&L across tracked holders: 31%.
Sector positioning — Other
GENB sits within the Other sector alongside 670 other tracked names. Compare whale ownership across peers:
How to use this page
Values are reported public positions from tracked 13F filers and disclosures — not real-time ownership totals. Open the live GENB dashboard for price charts and cross-investor scans, or read the SEC 13F guide.
Related stock holder pages
- INCY whale holders — Incyte Corporation
- BEIGF whale holders — BeOne Medicines Ltd.
- INSM whale holders — Insmed Incorporated
- MDGL whale holders — Madrigal Pharmaceuticals, Inc.
- ACAD whale holders — ACADIA Pharmaceuticals Inc.
- RVMDW whale holders — Revolution Medicines, Inc.
- CELC whale holders — Celcuity Inc.
- KOD whale holders — Kodiak Sciences Inc.
Learn more in Whale Analyzer Academy
Deepen your read on GENB with these Whale Analyzer Academy guides:
Frequently asked questions
Who owns GENB stock?
Whale Analyzer tracks 2 public institutional holders of GENB with a combined reported value of $28.2M. See the holder table above for the largest tracked positions.
Which top funds are buying GENB?
Tracked institutions were net buying last quarter — 2 increased. Check the "Change" column: "New" = fresh position, "Increased" = added, "Reduced" = trimmed.
How concentrated is GENB ownership?
The top five tracked holders report 100.0% of aggregate ownership.
Is GENB above or below the whale cost basis?
The aggregate tracked cost basis is $11.14 versus a current price of $16.47 (+47.9%).
What does 13F ownership mean for GENB?
Use the interactive GENB dashboard on Whale Analyzer for real-time holder analysis, or read our 13F Alpha Signals Guide.